Cas:6953-61-3 1-Naphthohydroxamic acid manufacturer & supplier

Chemical Name:1-Naphthohydroxamic acid

CAS.NO:6953-61-3

Synonyms:1-NAPHTHALENECARBOXAMIDE,N-HYDROXY;a-Naphthohydroxamic acid;N-hydroxynaphthalene-1-carboxamide;1-Naphthalenecarboxamide, N-hydroxy-;N-Hydroxy-1-naphthamide;1-naphthohydroxamic acid

Molecular Formula:C₁₁H₉NO₂

Molecular Weight:187.195

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.3±0.1 g/cm3

Index of Refraction:1.678

PSA:49.33000

Exact Mass:187.063324

LogP:1.49

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 1-NAPHTHALENECARBOXAMIDE,N-HYDROXY chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-naphthohydroxamic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Naphthalenecarboxamide, N-hydroxy- Use and application,a-Naphthohydroxamic acid technical grade,usp/ep/jp grade.

Related News: The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 1-Naphthohydroxamic acid manufacturer In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being. 1-Naphthohydroxamic acid supplier The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 1-Naphthohydroxamic acid vendor The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 1-Naphthohydroxamic acid factory In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.